Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan;45(1):90-8.
doi: 10.1016/j.ejca.2008.09.016. Epub 2008 Nov 6.

Management and outcome of stage 3 neuroblastoma

Shakeel Modak  1 , Brian H Kushner, Michael P LaQuaglia, Kim Kramer, Nai-Kong V Cheung
Affiliations

Management and outcome of stage 3 neuroblastoma

Shakeel Modak et al. Eur J Cancer. 2009 Jan.

Abstract

Purpose: The management of patients with International Neuroblastoma Staging System (INSS) stage 3 neuroblastoma (NB) is not consistent worldwide. We describe a single centre approach at Memorial Sloan-Kettering Cancer Centre (MSKCC) from 1991 to 2007 that minimises therapy except for those patients with MYCN-amplified NB.

Methods: In this retrospective analysis of 69 patients, tumour MYCN was not amplified in 53 and amplified in 16. Event-free survival (EFS) and overall survival (OS) were determined by Kaplan-Meier analysis.

Results: Fourteen patients with non-MYCN-amplified tumours were treated with surgery alone (group A) and the remaining 39 (group B) with surgery following chemotherapy that was initiated and administered at non-MSKCC institutions. Chemotherapy was discontinued after surgery in 38/39 of the latter. The 10-year EFS and OS for all patients with MYCN-non-amplified NB were 74.9+/-16.9% and 92.6+/-5.5%, respectively. There was no difference in OS between groups A and B (p=0.2; 10-year OS for groups A and B was 84.6+/-14% and 97.1+/-2.9%, respectively). Patients with MYCN-amplified disease (group C) underwent dose-intensive induction, tumour resection and local radiotherapy: 13 achieved complete or very good partial remission, and 10 received myeloablative chemotherapy. 11/16 patients also received 3F8-based immunotherapy: 10 remain free of disease. The 10-year EFS and OS for patients with MYCN-amplified neuroblastoma treated with immunotherapy were both 90.9+/-8.7%.

Conclusion: Patients with MYCN-non-amplified stage 3 NB can be successfully treated with surgery without the need for radiotherapy or continuation of chemotherapy. Combination of dose-intensive chemotherapy, surgery, radiotherapy and immunotherapy was associated with a favourable outcome for most patients with MYCN-amplified stage 3 NB.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest statement

None declared.

Figures

Fig. 1
Fig. 1
Memorial Sloan-Kettering Cancer Centre (MSKCC) algorithm for management of patients with International Neuroblastoma (NB) Staging System (INSS) stage 3 NB.
Fig. 2
Fig. 2
Distribution of patients with stage 3 NB.
Fig. 3
Fig. 3
Kaplan–Meier analysis for overall survival in patients with stage 3 NB: group A: patients with MYCN-non-amplified NB treated with surgical resection without chemotherapy; group B: MYCN-non-amplified NB patients treated with chemotherapy at non-MSKCC institutions prior to surgical resection and group C: patients with MYCN-amplified NB.
Fig. 4
Fig. 4
Kaplan–Meier analysis for event-free survival in patients with stage 3 NB.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993;11:1466–1477. - PubMed
    1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. pp. 933–970.
    1. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumour cell ploidy. J Clin Oncol. 2005;23:8819–8827. - PubMed
    1. Rubie H, Hartmann O, Michon J, et al. N-myc gene amplification is a major prognostic factor in localized neuroblastoma: results of a french NBL study. J Clin Oncol. 1997;15:1171–1182. - PubMed
    1. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24:2891–2896. - PubMed

Publication types